Skip to content

UroGen Pharma URGN Gross margin

Discontinued — last reported Q2 '21

Gross margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
70.5%0.0pp
Pfizer logo
PfizerPFE
73.5%+1.2pp
Johnson & Johnson logo
Johnson & JohnsonJNJ
67.8%-0.5pp
Merck & Co. logo
Merck & Co.MRK
73.9%-2.5pp
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
99.3%-0.5pp
Nuvation Bio logo
Nuvation BioNUVB
54.3%+39.5pp

Other financials

Income statement

See full
Revenue$51.0M+152%
Gross profit$11.6M
Operating income-$22.8M
Net income-$23.6M+46.2%
EPS (diluted)-$1.17

Balance sheet

See full
Cash & equivalents$110.0M+5.7%
Total debt$197.1M+56.0%
Total equity-$124.3M-167%
Total assets$253.7M+2.5%

Cash flow

See full
Operating cash flow-$45.3M-7.8%
CapEx$54.0K+22.7%
Free cash flow-$45.4M-7.8%

Valuation

See full
Market cap$1.71B+71.7%
Enterprise value$1.8B+80.9%
P/S12.2×+1.3×

Profitability

See full
Operating margin-329.7%
Net margin-94.8%-25.6pp
FCF margin-118.2%+1.3pp

Returns & leverage

See full
Return on equity-211.6%
Debt / equity4.8×
Current ratio4.7×-1.0×

Where this comes from

Calculated from UroGen Pharma’s reported figures.

Based on trailing twelve months.

The official record: UroGen Pharma’s 10-Q, filed August 4, 2021, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's gross margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is UroGen Pharma's gross margin?
UroGen Pharma (URGN) reported gross margin of 89.7% in Q2 2021.
What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.